Inhaled Nitric Oxide Delivery Systems Market Size & Share, by Type (Pediatric, Adult); Application (Hypoxemic Respiratory Failure Treatment, Acute Vasoreactivity Testing, Pulmonary Hypertension Treatment); End User (Ambulatory Center, Hospitals); Product (Disposables, Systems) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5855
  • Published Date: Mar 08, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024- 2036

Inhaled Nitric Oxide Delivery Systems Market size is expected to reach USD 3 Billion by the end of 2036, growing at a CAGR of 6% during the forecast period i.e., 2024-2036. In the year 2023, the industry size of inhaled nitric oxide delivery systems was over USD 600 Million. Hospital admission is required in over 50% of patients with asthma. The key factor fuelling the growth of the global market is increased R&D efforts which have led to novel applications for this technology in the healthcare sector. Moreover, the demand for inhaled nitric oxide delivery systemss worldwide is driven by an aging population with reduced lung function.

The market is growing as more and more people are using nitric oxide inhalation, a minimally invasive treatment. In a study conducted in 2020, inhaled nitric oxide has been shown to be effective in treating SARSCoV2 infection. It is also an effective treatment for COVID19 patients, as with conventional medicines. As a result, demand for inhaled nitric oxide delivery systemss increased during the pandemic.

Inhaled Nitric Oxide Delivery Systems Market
Get more information on this report: Request Free Sample PDF

Inhaled Nitric Oxide Delivery Systems Sector: Growth Drivers and Challenges

Growth Drivers

  • Growing Demand for Non-Invasive Treatment - The market size of the inhalation nitric oxide delivery systems is likely to be increased by increasing demand for noninvasive treatments, e.g. inhaled nitric oxide (INO). Noninvasive treatments are generally well tolerated and have fewer side effects than more invasive treatments, which may make them more attractive to patients and healthcare providers. Therefore, the demand for noninvasive treatments such as INO could increase and therefore nitric oxide delivery devices would be needed more.
  • Prevalence of Respiratory Disease - The growth of the inhaled nitric oxide delivery systems market over the forecast period is expected to be driven by an increase in the incidence and prevalence of respiratory disorders. The market for NO delivery systemss is further expected to be driven by an increasing incidence of respiratory infections such as SARS, COVID 19 and others. In the United States, approximately 1.8 million cases of coronavirus have been reported since May 2020. In addition, the United States Food and Drug Administration has approved an emergency use of a GENOSYL NO delivery systems manufactured by VERO Biotech in critically ill COVID19 patients with respiratory failure. The demand for inhaled nitric oxide delivery systemss in the country is expected to increase as a result of this trend.
  • High Prevalence of Hypoxemic Respiratory Failure in Pediatrics - In infants and children, inhaled nitric oxide is also used for the treatment of hypoxemic respiratory failure. This condition occurs when there's not enough oxygen in the blood. Various underlying conditions such as asthma, pneumonia and respiratory tract infections may also be to blame. INO works by relaxing the muscles on the walls of the blood vessels in the lungs, allowing the blood to flow more freely and increasing the amount of oxygen delivered to the tissues of the body.


  • Technical Complexities Associated – Current systemss are bulky and complex requiring trained professionals to operate and monitor. This can be a barrier to wider use, especially outside of intensive care units.
  • Safety Concerns Associated with the systems are expected to hamper the market growth in the forecast period
  • Evolving regulatory landscape are expected to hinder the nitric oxide delivery systems market growth in the projected period.

Inhaled Nitric Oxide Delivery Systems Market: Key Insights

Base Year


Forecast Year

2024 – 2036



Base Year Market Size (2023)

~USD 600 million

Forecast Year Market Size (2036)

~USD 3 billion

Regional Synopsis

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Inhaled Nitric Oxide Delivery Systems Segmentation

Type (Pediatric, Adult)

Based on type, pediatric segment in the inhaled nitric oxide delivery systems market is anticipated to hold 80% of the revenue share by 2036.  In the U.S. alone, nearly 25,000 to 30,000 neonatal HRF cases are reported annually and nearly 50% are cured using INO therapy. For 72 to 96 hours, the average cost of this treatment is almost 150 USD per hour, which represents a total of 97,000 to 130,000 USD per patient. Therefore, a favourable reimbursement policy has been established by the government of many countries in order to cover high healthcare costs and thus improve adoption of INO therapy for newborn children. In most adult infectious diseases, inhaled nitric oxide should be administered at high concentrations and due to a lack of clinical evidence this treatment has been less commonly used in adults. Nitric oxide inhalation is used to treat respiratory conditions in babies and newborns. These illnesses may include persistent pulmonary hypertension of the newborn, a severe condition that arises when a newborn's blood pressure in the lungs is abnormally high, and bronchopulmonary dysplasia, a chronic lung abnormality that can manifest in premature newborns. Treating these issues in infants and young children has shown promise when nitric oxide is inhaled. Therefore, the pediatric population has a significant need for inhaled nitric oxide delivery devices.

End User (Ambulatory Center, Hospitals)

Based on end user, the hospital segment in the inhaled nitric oxide delivery systems market is anticipated to hold 60% of the revenue share during the forecast period. This growth can be attributed to ease of delivery, the ability to liquidate when setting up INOs and monitoring systemss, a high number of personnel who monitor device operation as well as an emergency department. In the world, ARF mortality rates are around 30%. Life support and intensive care, like in the Intensive Care Unit of a hospital, is therefore essential for these patients. This segment is being driven by an increase in hospital admissions.

Our in-depth analysis of the global market includes the following segments:


  • Pediatric
  • Adult


  • Hypoxemic Respiratory Failure Treatment
  • Acute Vasoreactivity Testing
  • Pulmonary Hypertension Treatment

          End User

  • Ambulatory Center
  •  Hospitals


  • Disposables
  • Systems

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Inhaled Nitric Oxide Delivery Systems Industry - Regional Synopsis

North American Market Forecasts

The inhaled nitric oxide delivery systems market in the North America region is expected to record growth of 35% by the end of 2036. In the region, this growth is due to an increasing number of cases of HRF. Moreover, growth opportunities in the market are expected to be supported by increasing adoption of INO therapy, the presence of advanced medical infrastructure and favourable government initiatives. In the US, asthma affects more than 25 million people. In the United States, the inhaled nitric oxide delivery method is used on a regular basis in phase 2 and phase 3 clinical studies for acute respiratory distress syndrome. In 2020, more than 300,000 deaths from respiratory disorders were recorded in Canada. Five noteworthy respiratory disorders, counting asthma, constant obstructive pulmonary infection, lung cancer, tuberculosis, and cystic fibrosis, beset the larger part of Canadians. As these sicknesses ended up more predominant, the require for breathed in nitric oxide conveyance frameworks within the area is developing beside them. 

APAC Market Statistics

The inhaled nitric oxide delivery systems market in the Asia Pacific is expected to grow significantly by the end of 2036. In view of the growing pediatric population, an increase in patients with pulmonary failure, and the presence of locally produced nitric oxide disposables & systemss, the market continues to trend. The expansion of the market in this area is driven by efforts undertaken by governments and healthcare organizations to improve access to INO delivery systemss and treatments, with a particular emphasis on remote and unserved regions. As the region's smoking population rises, respiratory illnesses are also growing more prevalent. Nearly a million people in China are aware that they have COPD. This presents a big opportunity for marketers of INO delivery systemss since it has been clinically demonstrated that nitric oxide inhalation improves arterial blood flow's oxygenation and reduces the need for mechanical breathing assistance in patients with severe acute respiratory syndrome.

Research Nester
Inhaled Nitric Oxide Delivery System Market size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Inhaled Nitric Oxide Delivery Systems Landscape

    • Mallinckrodt Pharmaceuticals
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Getinge
    • Vero Biotech
    • LINDE
    • Beyond Air
    • SLE
    • NU MED
    • Bellerophon Therapeutics
    • Circassia Pharmaceuticals
    • Air Liquide Healthcare


In The News

  • The most up to date emphasis of VERO Biotech, Inc.'s tankless inhaled nitric oxide delivery systems gotten FDA endorsement. VERO Biotech, Inc. may be a commercial-stage healthcare company committed to the neonatal seriously care and intense care healing center community. The special highlights of the company's third era GENOSYL nitric oxide delivery systems permit quicker dosing, disentangled dealing with and more effective operation. 
  • Mallinckrodt Pharmaceuticals received permission from the Canadian regulatory authorities to use its NO delivery systems for COVID-19 patients.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 5855
  • Published Date: Mar 08, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The growing prevalence of respiratory disorder and increasing demand for non-invasive treatment are some of the major factors anticipated to drive the growth of the inhaled nitric oxide delivery systems market.

The market is anticipated to attain a CAGR of ~6% over the forecast period, i.e., 2024-2036.

The major players in the market are of Beyond Air, SLE, NU MED, Bellerophon Therapeutics, Mallinckrodt Pharmaceuticals, Air Liquide Healthcare, and others.

The hospital segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in North America is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Inhaled Nitric Oxide Delivery Systems Market Report Scope

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying